

Hyperinsulinemia (Metabolic Disorder) - Drugs in Development, 2021

<https://marketpublishers.com/r/H21763B05314EN.html>

Date: December 2021

Pages: 85

Price: US\$ 2,000.00 (Single User License)

ID: H21763B05314EN

Abstracts

Hyperinsulinemia (Metabolic Disorder) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia – Drugs In Development, 2021, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape.

Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue and frequently hungry. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes, and hypertension. Treatment includes Insulin secretion inhibiting agents, diet, exercise and other lifestyle changes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperinsulinemia – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hyperinsulinemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperinsulinemia (Metabolic Disorders) pipeline guide also reviews of key players

involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecule, respectively.

Hyperinsulinemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperinsulinemia (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hyperinsulinemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hyperinsulinemia (Metabolic Disorders)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hyperinsulinemia (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hyperinsulinemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Hyperinsulinemia - Overview
- Hyperinsulinemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hyperinsulinemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hyperinsulinemia - Companies Involved in Therapeutics Development
- AmideBio LLC
- Crinetics Pharmaceuticals Inc
- Eiger BioPharmaceuticals Inc
- Hanmi Pharmaceuticals Co Ltd
- PegBio Co Ltd
- Rezolute Inc
- Seneb BioSciences Inc
- XERIS Pharmaceuticals Inc
- Zealand Pharma AS
- Hyperinsulinemia - Drug Profiles
- Hyperinsulinemia - Dormant Projects
- Hyperinsulinemia - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hyperinsulinemia, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Hyperinsulinemia - Pipeline by AmideBio LLC, 2021
Hyperinsulinemia - Pipeline by Crinetics Pharmaceuticals Inc, 2021
Hyperinsulinemia - Pipeline by Eiger BioPharmaceuticals Inc, 2021
Hyperinsulinemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021
Hyperinsulinemia - Pipeline by PegBio Co Ltd, 2021
Hyperinsulinemia - Pipeline by Rezolute Inc, 2021
Hyperinsulinemia - Pipeline by Seneb BioSciences Inc, 2021
Hyperinsulinemia - Pipeline by XERIS Pharmaceuticals Inc, 2021
Hyperinsulinemia - Pipeline by Zealand Pharma AS, 2021
Hyperinsulinemia - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hyperinsulinemia, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Hyperinsulinemia (Metabolic Disorder) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/H21763B05314EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H21763B05314EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970